Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.

AIDS (London, England) - 13 Mar 2010

Verheyen Jens, Verhofstede Chris, Knops Elena, Vandekerckhove Linos, Fun Axel, Brunen Diede, Dauwe Kenny, Wensing Annemarie M J, Pfister Herbert, Kaiser Rolf, Nijhuis Monique

Abstract excerpt

OBJECTIVE: Bevirimat is the first drug of a new class of antivirals that hamper the maturation of HIV. The objective of this study was to evaluate the sequence variability of the gag region targeted by bevirimat in HIV subtype-B isolates. METHODS: Of 484 HIV subtype-B isolates, the gag region com...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to gag Gene Products, Human Immunodeficiency Virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Prevalence

Share to Succinates

Share to Triterpenes

Source

Identifiers

PMID: 19926962
DOI: 10.1097/QAD.0b013e32833160fa

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19926962-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.PMID 19926962Read ↗

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.Semantic proximity Read ↗

Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.Semantic proximity Read ↗

High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.Semantic proximity Read ↗

Determining and overcoming resistance to HIV protease inhibitors.Semantic proximity Read ↗

The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.Semantic proximity Read ↗

Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.Semantic proximity Read ↗

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.Semantic proximity Read ↗

HIV protease mutations leading to reduced inhibitor susceptibility.Semantic proximity Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.Semantic proximity Read ↗

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.Semantic proximity Read ↗

HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.